Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study

Purpose In large observational studies of adult kidney transplant recipients (KTRs) where older adults (65 years old and older) were not well represented, the mammalian target of rapamycin inhibitors (mTOR inhibitors) has poorer outcomes than the standard tacrolimus–mycophenolate–steroids (TAC–MPA–S) regimen. We conducted this study to compare the outcomes of regimens containing the common mTOR inhibitor, sirolimus (SRL) against TAC–MPA–S in older adult KTRs.